Pharmaceutical manufacturer Pfizer will submit data to the Food and Drug Administration later this month after announcing Friday its oral COVID-19 treatment “significantly reduced hospitalization and death” in trials.

The PAXLOVID treatment reduced the symptoms and duration of COVID-19 through the combination of a pill called PF-07321332 that blocks the release of an enzyme the coronavirus needs to replicate with a low dose of ritonavir, an antiviral medication used to help treat HIV. The company will submit data to the FDA “as soon as possible,” an action the CEO said the company will take before Thanksgiving.